# Agilent Technologies Inc. (A) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $150.86, market value $42.5 billion.

## Valuation
- **P/E (trailing): 29.8×** (5-yr avg 31.2×, 3-yr avg 28.3×). Agilent Technologies Inc. trades at 29.8× trailing earnings, close to its own five-year average of 31.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 7.06**. A PEG of 7.06 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 5.8×**. Each dollar of revenue is priced at 5.8×.
- **Price / book: 5.8×**. The shares trade at 5.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 23.1×**. Enterprise value is 23.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 3.0%** (5-yr avg 3.3%). Free cash flow equals 3.0% of the market value, in line with its five-year average of 3.3%.
- **Earnings yield: 3.4%**. The inverse of the P/E: 3.4% of the price is earned each year.

## Profitability
- **Operating margin: 22.2%**. 22.2% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 18.8%**. 18.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 19.3%**. 19.3% on shareholders' equity is solid.
- **Return on invested capital: 15.6%**. Return on all capital, debt included, is 15.6%: comfortably above what that capital costs.
- **Return on assets: 11.3%**. Each dollar of assets produces 11.3% of profit.

## Growth
- **Revenue growth (1 yr): 6.7%** (3-yr 0.5%/yr, 5-yr 5.4%/yr). Revenue grew 6.7% over the last year, against 5.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 3.2%** (3-yr 3.0%/yr, 5-yr 14.7%/yr). Earnings per share rose 3.2%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 4.1%/yr**. Free cash flow has compounded at 4.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.50**. Debt is 0.50 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 5.93**. A Z-score of 5.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.68%** ($1.01 per share, trailing). Agilent Technologies Inc. yields 0.68%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 22%** (23% of free cash flow). 22% of earnings goes out as dividends, leaving room to keep raising it.
- **Dividend growth (5 yr): 6.6%/yr** (1-yr -22.2%). The dividend has grown 6.6% a year over five years.

## Analyst view
- **Analyst consensus: buy** (20 analysts). 20 analysts cover Agilent Technologies Inc.; the consensus is buy, with an average price target of $174.40 (+16% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 18.4%** (YTD 11.5%, 3-mo 11.6%). The shares are up 18.4% over twelve months including dividends.
- **From 52-week high: -7.9%** (39.2% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.91** (volatility 33%). Beta of 0.91 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=A · Page: https://foliofundamentals.com/stocks/a

Not investment advice.